AVXL
Anavex Life Sciences Corp.
$2.39
+0.05 (+2.14%)
At close · Jul 17
Market Cap
$221.49M
Shares
92,671,758
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.39
Open$2.28
Day$2.26–2.43
52W$2.26–13.99
Avg vol 30d1.0M
Short int14.2M · 15.4% float · 6.9d
Short vol72%
Last earningsFeb 9, 2026
DataJan 2020–Jul 2026
Filing10-Q · Feb 9
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Feb 9, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.8 · elevated
Equity put/call 0.73
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−46%
below
Price vs 50-day avg
−12%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
1%
near low
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−55%
trailing
YTD return
−33%
this year
Relative strength
−62%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
15 of 193 funds reported for Jun 30 · net -35.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.35% of float · ▼ -18.8% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
193 holders — near 3-yr high, broad support
Squeeze score
74
high risk · 0–100
Fundamentals
EPS growth
−4%
Y/Y
Free cash flow
$-39.0M
Balance sheet
$102.6M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−46%
Bearish
Price vs 50-day avg
−12%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Distributing
15 of 193 funds reported for Jun 30 · net -35.1K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
15.35% of float · ▼ -18.8% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
193 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $2 · 1%
52-wk high $14
vs 200-day avg -46%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AVXL
this stock
Anavex Life Sciences Corp.
|
$221.49M | -32.9% | — | — | 15.4% |
|
ONC
BeOne Medicines Ltd.
|
$450.95B | +2.7% | +22179.2% | 917.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.26B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.94B | -12.2% | +20.8% | 16.5 | 3.3% |
|
ARGX
Argenx SE
|
$53.84B | +2.3% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AVXL | -4.4% | -10.5% | -54.6% | -7.7% | -32.9% |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | -2.9% | -10.8% | -62.4% | -7.3% | -41.9% |